AU2010236415A1 - Histone modification patterns for clinical diagnosis and prognosis of cancer - Google Patents

Histone modification patterns for clinical diagnosis and prognosis of cancer Download PDF

Info

Publication number
AU2010236415A1
AU2010236415A1 AU2010236415A AU2010236415A AU2010236415A1 AU 2010236415 A1 AU2010236415 A1 AU 2010236415A1 AU 2010236415 A AU2010236415 A AU 2010236415A AU 2010236415 A AU2010236415 A AU 2010236415A AU 2010236415 A1 AU2010236415 A1 AU 2010236415A1
Authority
AU
Australia
Prior art keywords
cancer
histone
levels
h3k4me2
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010236415A
Other languages
English (en)
Inventor
David W. Dawson
Siavash K. Kurdistani
David B. Seligson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2010236415A1 publication Critical patent/AU2010236415A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010236415A 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer Abandoned AU2010236415A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16921609P 2009-04-14 2009-04-14
US16921209P 2009-04-14 2009-04-14
US61/169,216 2009-04-14
US61/169,212 2009-04-14
US22516209P 2009-07-13 2009-07-13
US61/225,162 2009-07-13
PCT/US2010/031112 WO2010120942A2 (en) 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer

Publications (1)

Publication Number Publication Date
AU2010236415A1 true AU2010236415A1 (en) 2011-12-01

Family

ID=42983132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010236415A Abandoned AU2010236415A1 (en) 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer

Country Status (8)

Country Link
US (1) US20120094949A1 (https=)
EP (1) EP2419737A4 (https=)
JP (1) JP2012524278A (https=)
CN (1) CN102460173A (https=)
AU (1) AU2010236415A1 (https=)
BR (1) BRPI1013546A2 (https=)
CA (1) CA2758933A1 (https=)
WO (1) WO2010120942A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
CN104067125B (zh) * 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
WO2015102536A1 (en) * 2013-12-30 2015-07-09 Agency For Science, Technology And Research Methods for measuring biomarkers in gastrointestinal cancer
JP2016044993A (ja) * 2014-08-20 2016-04-04 有限会社マイテック ヒストン化学修飾判定による癌診断方法
AU2015340378B2 (en) * 2014-10-29 2021-08-12 Belgian Volition Sprl Method for the enrichment of circulating tumor DNA
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11015226B2 (en) * 2015-10-06 2021-05-25 Ontario Institute For Cancer Research (Oicr) Targeting the histone pathway to detect and overcome anthracyclin resistance
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
CA3033094A1 (en) * 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110221072B (zh) * 2019-06-10 2022-08-02 东南大学 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用
CN112904006B (zh) * 2021-01-28 2022-12-27 中山大学 一种乳腺癌预后预测分子标志物及其应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
WO2024233383A1 (en) * 2023-05-05 2024-11-14 University Of Utah Research Foundation Systems and methods for point-of-care assessment based on pathology image analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
ATE489624T1 (de) * 2005-04-29 2010-12-15 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Also Published As

Publication number Publication date
WO2010120942A2 (en) 2010-10-21
EP2419737A4 (en) 2013-02-13
JP2012524278A (ja) 2012-10-11
WO2010120942A3 (en) 2011-02-24
US20120094949A1 (en) 2012-04-19
CA2758933A1 (en) 2010-10-21
EP2419737A2 (en) 2012-02-22
CN102460173A (zh) 2012-05-16
BRPI1013546A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
US20120094949A1 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
Hsu et al. The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis
Nguyen Kovochich et al. HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma
Spizzo et al. Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer
Flem-Karlsen et al. Soluble AXL as a marker of disease progression and survival in melanoma
Dai et al. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK–Src signalling pathways
Tang et al. LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR/MAPK pathway in colorectal cancer
Relli et al. Distinct lung cancer subtypes associate to distinct drivers of tumor progression
Husa et al. EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer
Wang et al. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance
Shao et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer
Hokka et al. Psf3 is a prognostic biomarker in lung adenocarcinoma
He et al. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival
Kim et al. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
Takagi et al. Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring< 3 cm
Schlomm et al. Molecular staging of prostate cancer in the year 2007
EP2449383B1 (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
Wu et al. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma
Sasaroli et al. Novel surface targets and serum biomarkers from the ovarian cancer vasculature
Chen et al. Identification of nasopharyngeal carcinoma metastasis-related biomarkers by iTRAQ combined with 2D-LC-MS/MS
Fang et al. RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma
Ding et al. Targeting lysosomal protease CTSL promotes anti-tumor immunity and sensitizes HNSCC to PD-1 blockade by stabilizing PDK1 and activating Akt–PD-L1 axis
Huang et al. CLIP170 enhancing FOSL1 expression via attenuating ubiquitin-mediated degradation of β-catenin drives renal cell carcinoma progression
Zhao et al. HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach
Wang et al. Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period